Understanding Analyst Ratings: A Comprehensive Breakdown The standing of HealthEquity among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below ...

HealthEquity (NASDAQ:HQY – Get Free Report) was upgraded by analysts at Raymond James from an “outperform” rating to a “strong-buy” rating in a note issued to investors on Tuesday, MarketBeat.com ...

Similarly, Wells Fargo analyst Stan Berenshteyn has increased the price target for Healthequity to $125, maintaining an ...

Shares of HealthEquity, Inc. fell more than 17% on Wednesday, registering the worst drop since December 2021, after the health-savings account custodian projected near-term earnings that fell below ...

HealthEquity (NASDAQ:HQY – Free Report) had its price objective trimmed by The Goldman Sachs Group from $107.00 to $94.00 in a report published on Thursday morning,Benzinga reports. The firm currently ...

On a per-share basis, that figure was $0.69. This meant a mixed quarter for HealthEquity. While it beat the average analyst estimate of $305.8 million for revenue, it fell short of the consensus $ ...

HealthEquity, Inc. (NASDAQ:HQY) reported fourth-quarter adjusted EPS of 69 cents, up from 63 cents a year ago, missing the ...

Shares of HealthEquity (NASDAQ:HQY) fell ~20% on Wednesday, marking its biggest one-day decline in more than three years, after the health savings account (HSA) administrator failed to meet Street ...

and adjustments to ratings and price targets. Capture valuable insights into HealthEquity's market standing by understanding these analyst evaluations alongside pertinent financial indicators.

Raymond James analyst Gregory Peters upgraded Healthequity (HQY – Research Report) to a Buy yesterday and set a price target of $115.00. The ...

Barrington Research maintains HealthEquity with an Outperform and a $112 price target. Analyst Alexander Paris writes the earnings were impacted by excess costs associated with cyber-fraud ...